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LETTER TO THE EDITOR
CLINICAL MANIFESTATIONS SEEMED MORE SEVERE AMONG PATIENTS WITH ANTIBODY 4-FOLD 
OR A GREATER INCREASE IN TITER BOTH AGAINST pH1N1 AND AGAINST SEASONAL INFLUENZA 
THAN THOSE WHOSE ANTIBODY 4-FOLD OR GREATER INCREASE IN TITER WAS ONLY AGAINST 
ONE TYPE OF SEASONAL INFLUENZA
June 24, 2013
To the editor
In 2009, after an emergence of pandemic influenza A(H1N1) 
(pH1N1), one of our serological investigations showed 23 students 
whose paired serum antibodies simultaneously presented 4-fold or greater 
increase in titer both against pH1N1 and against seasonal influenza (SI). 
This caught our attention and in order to further understand clinical 
features of these cases, a case control study was conducted. From October 
2009 to September 2012, we collected the acute and convalescent phase 
serum samples from patients whose throat swabs were positive for 
pH1N1 or SI by real-time reverse transcription polymerase chain reaction 
(RT-PCR)5. The patients’ information, including clinical symptoms, self-
protect measures, and social activities after illness, was also collected 
through inspecting medical records, and interviewing face to face or by 
telephone. 
Paired blood samples were used to test antibodies against 2009 
pandemic A(H1N1) influenza virus and four kinds of seasonal influenza 
subtype virus (H3N2, H1N1, By, and Bv), which were detected by 
Hemagglutination inhibition (HI) assays. The influenza viruses used were 
A/GuangdongLiwan/SWL1538/2009 (H1N1), A/TianjinJinnan/15/2009 
(H1N1), A/FujianTongan/196/2009 (H3N2), B/JiangxiXiushui/32/2009 
Victoria, and B/Guangdong Xindong/134/2009 Yamagata. The HI 
assay was performed using a standard technique2. Serum samples 
were treated with receptor destroying enzyme to remove nonspecific 
hemagglutination. Serum samples were diluted in serial two-fold dilutions 
from 1:10 to 1:640 and then mixed with chicken red blood cells and the 
virus strain. HI titer was determined as the highest dilution of serum 
which showed hemagglutination inhibition.
During the study period, a total of 2,079 paired blood samples were 
collected, of which 68 cases (3.27%) whose antibodies were simultaneous 
4-fold or greater increase in titer against pH1N1 and SI. Among the 68 
cases, the sex distribution was 61.76% (N = 42) male and 39.14% (N 
= 26) female, the age ranged from five to 81 years old (median age = 
20), the patients had fevers ranging from 37.5 °C to 40.6 °C, the disease 
course lasted from two to 11 days. Primary clinical symptoms were a 
sore throat (65/68, 95.59%), a cough (37/68, 54.41%), and a headache 
(31/68, 45.59%). The proportion of patients who had arthralgia, nausea, 
vomiting and diarrhea was 8.82% (6/68), 7.35% (5/68), 4.41% (3/68), 
and 4.41% (3/68), respectively.
Of those whose antibodies presented 4-fold or greater increase in titer 
only against one subtype of SI, 136 cases were selected into a control 
group as a 1:2 match according to the following matching criteria: onset 
date (+/− 20 days), age (+/− 4 years), and sex. Compared to the control 
group (136 cases), the proportion of patients with a fever ≥ 38.5 °C, 
disease course ≥ 5 days, and clinical symptoms ≥ three episodes were 
significantly higher (p < 0.05) among the case group (68 cases) (Table 1). 
Taken together, we reported that of the 2079 influenza patients, 68 
cases were found to have simultaneous 4-fold or greater increase in 
serum antibody titers against pH1N1 and SI, these cases appeared to 
have more severe clinical pictures, including higher fever, longer disease 
course and more episodes of clinical symptoms. A possible explanation 
for this might be that these cases presented with a co-infection. Before 
emergence of pH1N1, co-infection has been proved to exist in seasonal 
Table 1 
Comparing the clinical characteristics between case group (68 cases) and 
control group (136 cases)
Clinical symptoms
Case group Control group
x2 p
No. % No. %
Fever ≥ 38.5 °C 26 38.24 33 24.27 4.30 0.04*
Disease course ≥ 5 days 19 27.94 14 10.29 10.41 0.00*
Cough 37 54.41 66 48.53 0.63 0.43
Sore throat 65 95.59 129 94.85 0.05 0.82
Headache 31 45.59 55 40.44 0.49 0.48
Nasal congestion 23 33.82 40 29.41 0.41 0.52
Rhino rhea 17 25.00 32 23.53 0.05 0.82
Sputum production 14 20.59 25 18.38 0.14 0.70
Fatigue 23 33.82 41 30.15 0.29 0.59
Myalgia 9 13.24 16 11.77 0.09 0.76
Chills 11 16.18 15 11.03 1.08 0.30
Arthralgia 6 8.82 15 11.03 0.24 0.63
Nausea 5 7.35 7 5.15 0.40 0.53
Vomiting 3 4.41 5 3.68 0.07 0.80
Diarrhea 3 4.41 2 1.47 1.64 0.20
Clinical symptoms ≥ 3  
episodes above
32 47.06 43 31.62 4.65 0.03*
*p < 0.05
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influenza. For example, NISHIKAWA et al. found a patient who was 
simultaneously infected with seasonal influenza A(H1N1) and A(H3N2) 
during the epidemic of 19813. In 2006, TODA et al. isolated the A/H3 
and B viruses from an influenza patient4. In addition, GOKA et al. also 
found co-infection was associated with higher risk of admission to ICU/
death1. Due to virus isolation not being conducted among our samples, 
more evidence regarding pH1N1 and SI needs to benefit from molecular 
virology research in future.
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